- Recommendation ID
- NG191/3
- Question
What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?
- Any explanatory notes
(if applicable) Suggested PICO (Population, Intervention, Comparator, Outcome)
P: patients 18 years and under who have COVID-19 pneumonia
I: treatment-dose LMWH
C: standard prophylaxis with LMWH
O:
• incidence of VTE
• mortality (all-cause, inpatient, COVID-19 related)
• admission to critical care (including use of advanced organ support)
• serious adverse events such as major bleeding or admission to hospital
Source guidance details
- Comes from guidance
- COVID-19 rapid guideline: managing COVID-19
- Number
- NG191
- Date issued
- March 2021
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/06/2021 |